<DOC>
	<DOCNO>NCT00518180</DOCNO>
	<brief_summary>This study evaluate safety immune response Novartis Meningococcal ACWY conjugate vaccine administer Tdap HPV vaccination healthy adolescent</brief_summary>
	<brief_title>A Study Evaluate Safety Immune Response Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>Healthy adolescent 1118 year age virgin ( male female ) intention become sexually active study period properly vaccinate diphtheria , tetanus , pertussis previous confirm suspected disease cause N. meningitidis ; previously immunize meningococcal vaccine receive prior human papillomavirus ( HPV ) vaccine ; serious acute , chronic progressive disease epilepsy , progressive neurological disease history GuillainBarre syndrome ; know suspected impairment/alteration immune function , either congenital acquire know bleed diathesis , condition may associate prolonged bleeding time ; Down 's syndrome know cytogenic disorder ;</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Meningococcal</keyword>
	<keyword>meningitis</keyword>
	<keyword>vaccine</keyword>
	<keyword>adolescent</keyword>
</DOC>